Skip to content
Nonprofiteer
← INTERNATIONAL AIDS VACCINE INITIATIVE INC

Form 990 for tax year 2023

Filed by INTERNATIONAL AIDS VACCINE INITIATIVE INC.

Totals

Total revenue
$129,678,400
Total expenses
$132,896,237
Contributions and grants received
$124,587,673
Grants paid
$31,255,891
Program service revenue
$2,297,276
Investment income
$2,762,423
Other revenue
$31,028
Total assets, end of year
$124,233,943
Total liabilities, end of year
$60,310,191
Net assets or fund balances, end of year
$63,923,752
Program services expenses (Part IX)
$112,549,400
Management and general expenses
$20,088,267
Fundraising expenses
$258,570
Program service expenses (Part III)
$112,549,400

Program services were 84.7% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1e · Government grants (contributions)

    $70,009,700

  • 1f · All other contributions, gifts and grants

    $54,577,973

  • 2a · Program service revenue: CONTRACT SERVICE FEES

    total $1,922,276 · related or exempt $1,922,276

  • 2b · Program service revenue: RESEARCH & DEVELOPMENT

    total $375,000 · related or exempt $375,000

  • 3 · Investment income

    total $3,256,766 · excluded $3,256,766

  • 7a · Gross sales of assets other than inventory

    securities $23,784,124

  • 7b · Less cost or other basis and sales expenses

    securities $24,278,467

  • 7c · Gain or loss

    securities -$494,343

  • 7d · Net gain or loss

    total -$494,343 · excluded -$494,343

  • 11a · Other revenue: MISCELLANEOUS

    total $31,028 · excluded $31,028

  • 11e · Other revenue, total

    $31,028

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $9,318,320 · program services $9,318,320

  • 3 · Grants to foreign organizations and individuals

    total $21,937,571 · program services $21,937,571

  • 5 · Compensation of officers, directors and key employees

    total $2,429,430 · program services $151,978 · management and general $2,277,452

  • 6 · Compensation of disqualified persons

    total $105,000 · management and general $105,000

  • 7 · Other salaries and wages

    total $36,453,779 · program services $25,840,589 · management and general $10,598,058 · fundraising $15,132

  • 8 · Pension plan contributions

    total $2,954,957 · program services $2,117,251 · management and general $836,597 · fundraising $1,109

  • 9 · Other employee benefits

    total $4,068,743 · program services $2,787,146 · management and general $1,280,146 · fundraising $1,451

  • 10 · Payroll taxes

    total $2,519,684 · program services $1,683,262 · management and general $835,548 · fundraising $874

  • 11b · Fees: legal

    total $1,090,452 · program services $258,674 · management and general $831,778

  • 11c · Fees: accounting

    total $215,651 · management and general $215,651

  • 11d · Fees: lobbying

    total $225,000 · fundraising $225,000

  • 11f · Fees: investment management

    total $89,219 · management and general $89,219

  • 11g · Fees: other

    total $798,898 · program services $60,000 · management and general $738,898

  • 13 · Office expenses

    total $850,783 · program services $512,843 · management and general $337,940

  • 14 · Information technology

    total $1,572,404 · program services $1,206,462 · management and general $365,942

  • 16 · Occupancy

    total $5,859,423 · program services $5,268,900 · management and general $590,523

  • 17 · Travel

    total $1,911,741 · program services $1,609,217 · management and general $300,881 · fundraising $1,643

  • 19 · Conferences, conventions and meetings

    total $404,539 · program services $348,430 · management and general $56,109

  • 22 · Depreciation, depletion and amortization

    total $1,545,566 · program services $1,468,855 · management and general $76,711

  • 23 · Insurance

    total $410,686 · program services $301,444 · management and general $109,242

  • 24a · Other expenses: RESEARCH&CLINICAL SVCS

    total $31,039,846 · program services $30,731,454 · management and general $308,392

  • 24b · Other expenses: LAB SUPPLIES/EQUIPMENT

    total $5,293,070 · program services $5,293,070

  • 24c · Other expenses: UNALLOWABLE COSTS

    total $1,138,668 · program services $1,083,411 · management and general $55,257

  • 24d · Other expenses: EQUIPMENT MAINT.

    total $367,321 · program services $339,834 · management and general $27,487

  • 24e · All other expenses

    total $295,486 · program services $230,689 · management and general $51,436 · fundraising $13,361

Balance sheet

Part X, book values.

  • 2 · Savings and temporary cash investments

    beginning of year $29,030,740 · end of year $34,403,229

  • 3 · Pledges and grants receivable

    beginning of year $53,415,955 · end of year $46,434,558

  • 4 · Accounts receivable

    beginning of year $472,428 · end of year $279,535

  • 9 · Prepaid expenses and deferred charges

    beginning of year $613,872 · end of year $146,763

  • 10a · Land, buildings and equipment: cost or other basis

    $47,610,615

  • 10b · Land, buildings and equipment: accumulated depreciation

    $46,683,234

  • 10c · Land, buildings and equipment, net

    beginning of year $2,254,328 · end of year $927,381

  • 11 · Investments: publicly traded securities

    beginning of year $31,756,089 · end of year $33,407,409

  • 15 · Other assets

    beginning of year $11,405,072 · end of year $8,635,068

  • 17 · Accounts payable and accrued expenses

    beginning of year $7,733,196 · end of year $9,420,265

  • 18 · Grants payable

    beginning of year $13,914,391 · end of year $11,781,746

  • 19 · Deferred revenue

    beginning of year $27,962,390 · end of year $28,968,880

  • 25 · Other liabilities

    beginning of year $13,071,453 · end of year $10,139,300

  • 27 · Net assets without donor restrictions

    beginning of year $35,250,334 · end of year $32,056,013

  • 28 · Net assets with donor restrictions

    beginning of year $31,016,720 · end of year $31,867,739

Mission and programs · 2023

Mission

A NONPROFIT SCIENTIFIC RESEARCH ORGANIZATION THAT DEVELOPS VACCINES AND ANTIBODIES FOR HIV, TUBERCULOSIS, EMERGING INFECTIOUS DISEASES, AND NEGLECTED DISEASES.

Activities or mission (Part I)

TRANSLATE SCIENTIFIC DISCOVERIES INTO AFFORDABLE, GLOBALLY ACCESSIBLE PUBLIC HEALTH SOLUTIONS

  • RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED DOZENS OF HIV VACCINE CANDIDATES INTO EARLY STAGE CLINICAL TRIALS, INCLUDING A VACCINE THAT RECENTLY YIELDED PROMISING RESULTS AND IS PART OF AN EXCITING NEW APPROACH TO HIV VACCINE DESIGN. OTHER NOTABLE ACHIEVEMENTS INCLUDE THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE HIV BURDEN IS GREATEST, AND THE FIRST TRIAL OF AN MRNA HIV VACCINE CANDIDATE IN AFRICA. IAVI HAS CONDUCTED MORE THAN 50 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING, COUNSELING SERVICES, AND HEALTH CARE REFERRALS TO MORE THAN 870,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS, LASSA FEVER, MARBURG, EBOLA SUDEN, AND COVID-19, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF THE RESEARCH IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST. IAVI ALSO SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS.

    Expenses $112,549,400 · Grants $31,255,891 · Revenue $2,297,276

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Mark B Feinberg

    PRESIDENT/CEO

    Total calculated
    $829,866
    From this org
    $719,151
    From related orgs
    $0
    Other
    $110,715
    Hours/week
    35

    Schedule J breakdown matched by us

    Base
    $617,215
    Bonus
    $59,460
    Other
    $42,476
    Deferred
    $109,168
    Nontaxable benefits
    $1,547
    Filer's total
    $829,866

  • Eric Paul Goosby

    BOARD CHAIR

    Total calculated
    $0
    Hours/week
    2

  • Robert Goldberg

    BOARD TREASURER

    Total calculated
    $0
    Hours/week
    2

  • Linda-Gail Becker

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • David Blumberg

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Jim Connolly

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Mark Dybul

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Wafaa El-Sadr

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Alexis M Pinto

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • John W Shiver

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Susan Silbermann

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Anne Martin Simonds

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Rajeev Venkayya

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Marijke Wijnroks

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1

  • Ana Cespedes Montoya

    CHIEF OPERATING OFFICER

    Total calculated
    $610,355
    From this org
    $531,087
    From related orgs
    $0
    Other
    $79,268
    Hours/week
    35

    Schedule J breakdown matched by us

    Base
    $458,567
    Bonus
    $42,520
    Other
    $30,000
    Deferred
    $54,567
    Nontaxable benefits
    $24,701
    Filer's total
    $610,355

  • Louis D Schwartz

    ASST. SEC. & CFAO

    Total calculated
    $467,106
    From this org
    $390,586
    From related orgs
    $0
    Other
    $76,520
    Hours/week
    35

    Schedule J breakdown matched by us

    Base
    $330,037
    Bonus
    $30,549
    Other
    $30,000
    Deferred
    $40,367
    Nontaxable benefits
    $36,153
    Filer's total
    $467,106

  • Min Ding

    GEN. COUNS. & SEC.

    Total calculated
    $405,829
    From this org
    $333,986
    From related orgs
    $0
    Other
    $71,843
    Hours/week
    35

    Schedule J breakdown matched by us

    Base
    $276,176
    Bonus
    $27,810
    Other
    $30,000
    Deferred
    $35,690
    Nontaxable benefits
    $36,153
    Filer's total
    $405,829

  • Mario Gagliano

    CPO, VP OF HR (FROM 9/23)

    Total calculated
    $116,275
    From this org
    $102,045
    From related orgs
    $0
    Other
    $14,230
    Hours/week
    35

  • Swati Gupta

    VP, HEAD OF EID & EPIDEM.

    Total calculated
    $455,691
    From this org
    $379,201
    From related orgs
    $0
    Other
    $76,490
    Hours/week
    35

    Schedule J breakdown matched by us

    Base
    $317,567
    Bonus
    $31,634
    Other
    $30,000
    Deferred
    $40,597
    Nontaxable benefits
    $35,893
    Filer's total
    $455,691

  • Dagna Laufer

    VP & HEAD OF CLINICAL DEV.

    Total calculated
    $435,336
    From this org
    $394,188
    From related orgs
    $0
    Other
    $41,148
    Hours/week
    35

    Schedule J breakdown matched by us

    Base
    $333,637
    Bonus
    $30,551
    Other
    $30,000
    Deferred
    $39,206
    Nontaxable benefits
    $1,942
    Filer's total
    $435,336

  • Christopher Parks - Assoc

    AVP. VIRAL VAC. & HEAD OF DDL

    Total calculated
    $427,323
    From this org
    $365,204
    From related orgs
    $0
    Other
    $62,119
    Hours/week
    35

    Schedule J breakdown matched by us

    Base
    $305,862
    Bonus
    $29,342
    Other
    $30,000
    Deferred
    $37,656
    Nontaxable benefits
    $24,463
    Filer's total
    $427,323

  • Eric Skjeveland

    VP, BUSINESS DEVELOPMENT

    Total calculated
    $378,110
    From this org
    $341,395
    From related orgs
    $0
    Other
    $36,715
    Hours/week
    35

    Schedule J breakdown matched by us

    Base
    $285,620
    Bonus
    $25,775
    Other
    $30,000
    Deferred
    $34,650
    Nontaxable benefits
    $2,065
    Filer's total
    $378,110

  • Sangeetha Sagar

    VP & HEAD OF PRODUCT DEV

    Total calculated
    $409,551
    From this org
    $376,047
    From related orgs
    $0
    Other
    $33,504
    Hours/week
    35

    Schedule J breakdown matched by us

    Base
    $360,822
    Bonus
    $7,875
    Other
    $7,350
    Deferred
    $32,784
    Nontaxable benefits
    $720
    Filer's total
    $409,551

  • Frances Sinha

    FORMER OFFICER

    Total calculated
    $105,000
    From this org
    $105,000
    From related orgs
    $0
    Other
    $0
    Hours/week
    35

    Schedule J breakdown matched by us

    Base
    $105,000
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $105,000

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Form 990 of other organizations
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee
  • 4a · Severance or change-of-control payment
  • 7 · Other non-fixed payments

Answered no

  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 4A
FRANCES SINHA WAS PAID $105,000 IN SEVERANCE FOR 2023.
PART I, LINE 7
BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II).

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

The 10 largest by cash amount. The API serves every itemized grant.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

  • STICHTING IAVI

    N/A · RESEARCH SUPPORT · NL · controlled entity

    Directly controlled by IAVI INC

  • IAVI INDIA

    N/A · RESEARCH SUPPORT · IN · controlled entity

    Directly controlled by IAVI INC

  • IAVI SOUTH AFRICA NPC (IAVI-SA)

    N/A · RESEARCH SUPPORT · SF · controlled entity

    Directly controlled by IAVI INC

  • IAVI AFRICA LIMITED

    N/A · RESEARCH SUPPORT · KE · controlled entity

    Directly controlled by IAVI INC

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Disregarded entities

Part I: entities that legally are the filer and file no return of their own.

  • IAVI LAB LLC

    LAB RESEARCH · DE · income $0 · assets $0

    Directly controlled by IAVI INC

  • IAVI GLOBAL HEALTH IMPACT LLC

    FACILITATE PRODUCT DEVELOPMENT AND/OR COMMERCIALIZATION · DE · income $0 · assets $0

    Directly controlled by IAVI INC

Provenance

Return type
form_990
Tax year
2023
Filed
22 July 2024
IRS schema version
2023v5.1
Source object
202412049349300811

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.